hapabapa/iStock Editorial via Getty Images
- AbbVie (NYSE:ABBV) said it will incur a negative impact of $0.42 to GAAP and non-GAAP diluted earnings per share in Q2 due to acquired IPR&D and milestones expense of $823M.
- As a result, the company now sees Q2 adjusted diluted earnings per share of $2.84-$2.88. Consensus is $3.18.
- AbbVie also said that its full-year EPS guidance range is now $11.67-$11.87. Consensus is $12.24.